Targeted Disease(s):
COPD|Other
Purpose of Study:
A phase 2a randomized, placebo-controlled clinical study to evaluate the efficacy and safety of MK5475 in adults with pulmonary hypertension associated with Chronic Obstructive Pulmonary Disease.
Study Dates:
March 16, 2023 - September 15, 2026
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Lead Institution:
Merck & Co., Inc.
Funding Source:
Merck & Co., Inc.
Sponsors:
Merck & Co., Inc.
Contact:
Phone: 1-888-577-8839
Email: [email protected]
ClinicalTrails.gov Identifier:
NCT05612035
